AL3 and PL3 also received an intravenous dose of Boch1D10F1 (1 or 2 mg/kg) on day 0 as well as a subcutaneous injection of 0.5 mg/kg meloxicam (Metacam) on day 0, 7, and 14, because the combination of PD-1/PD-L1 blockade and COX-2 inhibition represents a promising strategy to synergistically enhance the antiviral T-cell response during BLV infection [12, 30]. This evidence concerns the gene CD274 and deltaretrovirus infections.